Roadmap

Develop in stages.
Advance with evidence.

A proposed sequence, subject to resources, institutional permissions, validation, and regulatory advice. Time windows begin from a start date that has not yet been set.

Available today

A public starting point.

Our company website and CP Board Review learning website are online. Explore the learning platform while clinical products continue through development and evaluation.

Open CP Board Review

Near term
0–6 months
Proposed

Establish the foundations

Complete blinded independent dual-reader reassessment and prepare the manuscript for submission.
Document data, software, and results ownership with the institution and relevant rights holders.
Confirm employment, outside-work, and conflict-of-interest requirements.
Verify the already-established company's registration details and conduct trademark checks.
Expand the published company website and release additional reviewed learning modules.
Arrange an institutionally approved health check phrase-tool pilot.

Prerequisites: research permissions, reader availability, rights review, approved public content, and a defined pilot scope.

Risks and tradeoffs: reassessment may change conclusions; review delays public release but reduces premature claims. Manuscript submission does not imply acceptance.

Medium term
6–18 months
Proposed

Test transferability

Conduct multi-center external validation of CZE-IS triage.
Consult TFDA on software-as-a-medical-device classification.
Productize health check reporting support for other centers.
Expand the available CP Board Review website, develop reviewed case-quiz modules, and evaluate an appropriate membership model.

Prerequisites: multi-center agreements and ethics review, defined intended use, compatible data formats, reviewed content, and support capacity.

Risks and tradeoffs: external performance may differ; integration and validation add cost. Earlier regulatory consultation may reduce later redesign. Membership adds ongoing content and customer-service obligations.

Long term
Beyond 18 months
Proposed

Expand within a defined scope

Decide whether and how to pursue registration based on TFDA's classification.
Investigate other laboratory interpretation areas, such as urine/CSF IFE and free light chains.
Develop inter-institutional collaboration and educational licensing.

Prerequisites: classification advice, appropriate evidence and quality documentation, confirmed rights, and resources for each new intended use.

Risks and tradeoffs: new specimen types require separate validation; broader scope increases support and regulatory obligations. A narrower initial scope may improve feasibility.

Milestones are conditional

This roadmap is a planning draft, not a promise of clinical availability, approval, or a fixed launch date. Company establishment is founder-confirmed; specific registration details remain to be verified.